Cardiovascular disease risk assessment in patients with obstructive sleep apnoea: Clinical utility of the Framingham risk equation for initiating statins

Diabetes, Obesity and Metabolism

Volumn 10, Issue 2, 2008, Pages 181-182

  Horwood, F ^a   Gruber, A ^a   Sithole, J ^b   Ali, N ^a   Idris, I ^a,c  

^a SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c KING S MILL HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular risk; JBS 2 guideline; Obstructive sleep apnoea

Indexed keywords

ANTILIPEMIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALGORITHM; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHI SQUARE TEST; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIASTOLIC BLOOD PRESSURE; DIFFERENTIAL DIAGNOSIS; EPWORTH SLEEPINESS SCALE; HUMAN; INTERMETHOD COMPARISON; OBESITY; POSITIVE END EXPIRATORY PRESSURE; PRIMARY PREVENTION; RANK SUM TEST; RISK ASSESSMENT; SLEEP APNEA SYNDROME; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SYSTOLIC BLOOD PRESSURE; TASK PERFORMANCE;

EID: 38049100845     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00732.x     Document Type: Article

References (10)

1. Shahar E, Whitney CW, Redline S et al. Sleep-disordered breathing and cardiovascular disease: Cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19-25.
2. Peker Y, Carlson, Hedner J. Increased incidence of coronary artery disease in sleep apnoea: A long term follow-up. Eur Respir J 2006; 28: 592-602.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Eng J Med 1998; 339: 229-234.
4. West SD, Nicoll DJ, Stradling JR. Prevalence of obstructive sleep apnoea in patients with type 2 diabetes. Thorax 2006; 61: 945-50. Epub.
5. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: Meta-analysis of randomised controlled trials. BMJ 2006; 332: 1115-1118.
6. JBS-2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(Suppl. 5): v1-v52.
7. Schafer H, Pauleit D, Sudhop T, Gouni-Berthold I, Ewig S, Berthold HK. Body fat distribution, serum leptin, and cardiovascular risk factors in men with obstructive sleep apnea. Chest 2002; 122: 829-839.
8. Quan SF, Gersh BJ. Cardiovascular consequences of sleep-disordered breathing: Past, preRent and future: report of a workshop from the National Center on Sleep Disorders Research and the National Heart, Lung, and Blood Institute. Circulation 2004; 109: 951-957.
9. Brindle PM, Beswick AD, Fahey T, Ebrahim SB. The accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: A systematic review. Heart. 2006; 92: 1752-9. Epub.
10. Whitely L, Padmanathan S, Hole D, Isles C. Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care 2005; 28: 1588-1593.